Scarica l'app Stockscreener
5.1601
1.71%
-0.0899
Precedente Chiudi:
$5.25
Aprire:
$5.28
Volume 24 ore:
155.30K
Relative Volume:
0.41
Capitalizzazione di mercato:
$290.62M
Reddito:
-
Utile/perdita netta:
$-56.83M
Rapporto P/E:
-5.1601
EPS:
-1
Flusso di cassa netto:
$-53.00M
1 W Prestazione:
-2.82%
1M Prestazione:
+21.70%
6M Prestazione:
+189.89%
1 anno Prestazione:
+232.91%
Intervallo 1D:
$5.15
$5.35
Intervallo di 1 settimana:
$4.98
$5.49
Portata 52W:
$0.72
$6.0999
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Rezolute Inc Borsa (RZLT) Ultime notizie
Where are the Opportunities in (RZLT) - Stock Traders Daily
Federated Hermes Inc. Has $48.50 Million Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - MSN
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of “Buy” by Brokerages - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $10.75 - MarketBeat
Rezolute Inc (RZLT) rating initates by Guggenheim - Knox Daily
Rezolute (NASDAQ:RZLT) Given New $15.00 Price Target at BTIG Research - Defense World
Rezolute shares maintain Buy rating from H.C. Wainwright on FDA update - Investing.com Canada
Rezolute Gains 13%, Insider Trades Reap Benefit - Simply Wall St
Rezolute (NASDAQ:RZLT) Price Target Raised to $15.00 - MarketBeat
Rezolute Inc (RZLT) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study - Yahoo Finance
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study - Zacks Investment Research
Rezolute (NASDAQ:RZLT) Receives Buy Rating from HC Wainwright - Defense World
FDA authorises US trial of Rezolute’s drug candidate for congenital hyperinsulinism - Yahoo Finance
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - ETHealthWorld
Rezolute's (RZLT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
RZLT’s latest rating updates from top analysts. - Knox Daily
US FDA lifts partial clinical hold on Rezolute’s blood sugar treatment - WHBL
Peninsula drug maker plots late-stage clinical trial after FDA lifts delay - San Francisco Business Times
Jones Trading maintains Buy rating on Rezolute shares with no price target change - Investing.com Canada
RZLT’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Healthy Upside Potential: Rezolute Inc (RZLT) - SETE News
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment - Benzinga
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - Reuters
Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy (NASDAQ:RZLT) - Seeking Alpha
US FDA lifts partial clinical hold on Rezolute’s low blood sugar treatment - PharmaLive
FDA lifts hold on Rezolute's hyperinsulinism therapy study - Investing.com
US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - AOL
Rezolute Shares Rise Premarket After FDA Lifts Partial Study Holds - MarketWatch
Rezolute’s RZ358 Advances with FDA Clearance for Study - TipRanks
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study - StockTitan
Pleasing Signs As A Number Of Insiders Buy Rezolute Stock - Yahoo Finance
Guggenheim Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - Nasdaq
Rezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Guggenheim - Defense World
Rezolute (NASDAQ:RZLT) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Rezolute to Participate in Upcoming Investor Conferences - StockTitan
BTIG Research gives a Buy recommendation for Rezolute Inc (RZLT) - Knox Daily
Vanguard Group Inc. Grows Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat
Vanguard Group Inc. Buys 145,700 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Contrasting Atreca (NASDAQ:BCEL) and Rezolute (NASDAQ:RZLT) - Defense World
Virtu Financial LLC Acquires Shares of 14,410 Rezolute, Inc. (NASDAQ:RZLT) - Defense World
BTIG Research initates Rezolute Inc (RZLT) stock to a Buy - Knox Daily
Rezolute’s (RZLT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Rezolute (NASDAQ:RZLT) PT Raised to $10.00 - Defense World
HC Wainwright Reaffirms "Buy" Rating for Rezolute (NASDAQ:RZLT) - MarketBeat
Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at Maxim Group - MarketBeat
FDA clears Rezolute's phase 3 trial for rare disease therapy - Investing.com
FDA clears Rezolute's phase 3 trial for rare disease therapy - Investing.com India
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
4,300 |
16,828 |
54,352 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 14 '24 |
Buy |
3.91 |
3,300 |
12,916 |
13,000 |
| Evans Daron | CFO |
Jun 14 '24 |
Buy |
4.04 |
40,000 |
161,568 |
40,000 |
| Evans Daron | CFO |
May 29 '24 |
Buy |
3.50 |
451 |
1,578 |
121,351 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
May 23 '24 |
Buy |
2.69 |
7,500 |
20,138 |
50,052 |
| Evans Daron | CFO |
May 24 '24 |
Buy |
3.23 |
2,942 |
9,503 |
13,000 |
| Evans Daron | CFO |
May 23 '24 |
Buy |
2.85 |
58 |
165 |
10,058 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Mar 28 '24 |
Buy |
2.55 |
500 |
1,275 |
1,076 |
| Evans Daron | CFO |
Mar 15 '24 |
Buy |
1.69 |
20,000 |
33,830 |
20,000 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Mar 14 '24 |
Buy |
1.88 |
10,000 |
18,800 |
10,000 |
1.26%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):